CY1123856T1 - Αντικαρκινικες συνθεσεις - Google Patents
Αντικαρκινικες συνθεσειςInfo
- Publication number
- CY1123856T1 CY1123856T1 CY20211100068T CY211100068T CY1123856T1 CY 1123856 T1 CY1123856 T1 CY 1123856T1 CY 20211100068 T CY20211100068 T CY 20211100068T CY 211100068 T CY211100068 T CY 211100068T CY 1123856 T1 CY1123856 T1 CY 1123856T1
- Authority
- CY
- Cyprus
- Prior art keywords
- arn
- prostate cancer
- meth
- poly
- acrylate copolymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση αφορά φαρμακοτεχνικές μορφές του ARN-509, οι οποίες μπορεί να χορηγηθούν σε ένα θηλαστικό, συγκεκριμένα σε έναν άνθρωπο, που πάσχει από μια ασθένεια ή πάθηση που σχετίζεται με τον υποδοχέα των ανδρογόνων (AR), συγκεκριμένα καρκίνο, πιο συγκεκριμένα καρκίνο του προστάτη, που περιλαμβάνει μεταξύ άλλων τον ευνουχοάντοχο καρκίνο του προστάτη, τον μεταστατικό ευνουχοάντοχο καρκίνο του προστάτη, τον μεταστατικό ευνουχοάντοχο καρκίνο του προστάτη χωρίς προηγούμενη έκθεση σε χημειοθεραπεία, τον βιοχημικά υποτροπιάζοντα ορμονο-εξαρτώμενο καρκίνο του προστάτη, ή τον υψηλού κινδύνου, μη-μεταστατικό ευνουχοάντοχο καρκίνο του προστάτη. Σε μία άποψη, αυτές οι φαρμακοτεχνικές μορφές περιλαμβάνουν μια στερεή διασπορά του ARN-509 και ένα πολυ(μεθ)ακρυλικό συμπολυμερές. Σε μία άποψη, μπορεί να ληφθεί η στερεή διασπορά του ARN-509 και ένα πολυ(μεθ)ακρυλικό συμπολυμερές. συγκεκριμένα λαμβάνεται ένα μίγμα με τήξη-εξώθηση που περιλαμβάνει το ARN-509 και ένα πολυ(μεθ)ακρυλικό συμπολυμερές και προαιρετικά στη συνέχεια το εν λόγω μίγμα τήξης-εξώθησης αλέθεται. Σε μία άποψη, μπορεί να ληφθεί η στερεή διασπορά του ARN-509 και ένα πολυ(μεθ)ακρυλικό συμπολυμερές, συγκεκριμένα λαμβάνεται ένα μίγμα με ξήρανση με ψεκασμό που περιλαμβάνει το ARN-509 και ένα πολυ(μεθ)ακρυλικό συμπολυμερές σε έναν κατάλληλο διαλύτη.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 | ||
| PCT/US2015/063667 WO2016090101A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123856T1 true CY1123856T1 (el) | 2022-05-27 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100068T CY1123856T1 (el) | 2014-12-05 | 2021-01-27 | Αντικαρκινικες συνθεσεις |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20170360707A1 (el) |
| EP (2) | EP3226842B1 (el) |
| JP (1) | JP6767368B2 (el) |
| KR (1) | KR102348325B1 (el) |
| CN (2) | CN115837010A (el) |
| AR (1) | AR102924A1 (el) |
| AU (1) | AU2015358493B2 (el) |
| CA (1) | CA2969661C (el) |
| CL (1) | CL2017001372A1 (el) |
| CO (1) | CO2017005573A2 (el) |
| CR (1) | CR20170217A (el) |
| CY (1) | CY1123856T1 (el) |
| DK (1) | DK3226842T3 (el) |
| EA (1) | EA035988B1 (el) |
| ES (1) | ES2839128T3 (el) |
| HR (1) | HRP20201902T1 (el) |
| HU (1) | HUE051888T2 (el) |
| IL (1) | IL252324B (el) |
| LT (1) | LT3226842T (el) |
| MA (2) | MA55404A (el) |
| MD (1) | MD3226842T2 (el) |
| MX (1) | MX2017007201A (el) |
| NI (1) | NI201700069A (el) |
| PL (1) | PL3226842T3 (el) |
| PT (1) | PT3226842T (el) |
| RS (1) | RS61466B1 (el) |
| SG (1) | SG11201704264UA (el) |
| SI (1) | SI3226842T1 (el) |
| TW (1) | TWI683662B (el) |
| UA (1) | UA121123C2 (el) |
| WO (1) | WO2016090101A1 (el) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104661658A (zh) | 2012-09-26 | 2015-05-27 | 阿拉贡药品公司 | 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素 |
| EP3226843B1 (en) | 2014-12-05 | 2021-05-26 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| CN111479560A (zh) | 2017-10-16 | 2020-07-31 | 阿拉贡药品公司 | 用于治疗非转移性去势难治性前列腺癌的抗雄激素 |
| ES2967689T3 (es) * | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| WO2020144649A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising enzalutamide dispersed in apple sauce |
| CN113365623A (zh) | 2019-01-30 | 2021-09-07 | 阿拉贡药品公司 | 用于治疗转移性去势敏感性前列腺癌的抗雄激素 |
| WO2020157704A1 (en) | 2019-01-30 | 2020-08-06 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP4054572A1 (en) | 2019-11-04 | 2022-09-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2024189186A1 (en) | 2023-03-16 | 2024-09-19 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE324886T1 (de) | 2001-04-02 | 2006-06-15 | Astrazeneca Ab | Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp |
| JPWO2003077827A1 (ja) * | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | 医薬固体分散体の製造方法 |
| AU2003292509B2 (en) * | 2003-12-15 | 2007-08-02 | Council Of Scientific And Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer |
| ES2593379T3 (es) * | 2006-03-27 | 2016-12-09 | The Regents Of The University Of California | Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos |
| US9108944B2 (en) * | 2010-02-16 | 2015-08-18 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| WO2012174436A1 (en) * | 2011-06-15 | 2012-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| CA3008345C (en) | 2012-06-07 | 2019-10-22 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| CN109897004A (zh) * | 2012-09-11 | 2019-06-18 | 麦迪威森前列腺医疗有限责任公司 | 恩杂鲁胺制剂 |
| CN104661658A (zh) * | 2012-09-26 | 2015-05-27 | 阿拉贡药品公司 | 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素 |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| BR112015015758B1 (pt) * | 2013-01-22 | 2022-01-04 | F. Hoffmann-La Roche Ag | Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| BR112016002970A2 (pt) * | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
| CA2940984A1 (en) * | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
-
2015
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en active Application Filing
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh active
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 CN CN202211487545.0A patent/CN115837010A/zh active Pending
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 MX MX2017007201A patent/MX2017007201A/es unknown
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro unknown
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active IP Right Grant
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 EP EP20209559.2A patent/EP3842034A1/en active Pending
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2020
- 2020-11-30 HR HRP20201902TT patent/HRP20201902T1/hr unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123856T1 (el) | Αντικαρκινικες συνθεσεις | |
| CY1124504T1 (el) | Αντικαρκινικες συνθεσεις | |
| EA201791222A1 (ru) | Противораковые композиции | |
| CY1124293T1 (el) | Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου | |
| CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| CL2017003427A1 (es) | Anticuerpos para cd40 | |
| CL2017001515A1 (es) | Receptores de antígeno químericos bcma | |
| CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| EA201591740A1 (ru) | Вирусы болезни ньюкасла и их применение | |
| CY1121315T1 (el) | Απο του στοματος χορηγουμενες συνθεσεις της δεφερασιροξης | |
| EA201592103A2 (ru) | Способы и композиции для усиления cd4+ регуляторных t-клеток | |
| EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
| NI201800127A (es) | Composiciones antineoplásicas | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA201790650A1 (ru) | Лекарственная форма и способы применения абиратерона ацетата | |
| CY1124738T1 (el) | Συνθεσεiς εμβολιων που περιλαμβανουν τρυπτοφανη 2,3-διοξυγεναση ή θραυσματα αυτης | |
| EA202190633A1 (ru) | Лекарственные формы для применения в педиатрии, способы получения и применения | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| BR112018076287A2 (pt) | métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária | |
| EA201692405A1 (ru) | Новые соединения, применимые в качестве ингибиторов s100 | |
| EA201591899A1 (ru) | Введение nsaid и соответствующие композиции, способы и системы | |
| AR108690A1 (es) | Anticuerpos contra el miembro 21 de la superfamilia del receptor del factor de necrosis tumoral (anti-tnfrsf21) y métodos de uso de los mismos |